Ditch Labs

Nicotine addiction is one of the most pressing public health challenges, contributing to over 8 million deaths annually worldwide. Despite decades of efforts, more than 1.2 billion people still smoke, and over 80 million use e-cigarettes, with relapse rates exceeding 90% for those attempting to quit without effective intervention. Existing Nicotine Replacement Therapies (NRTs) have limited success due to poor adherence, imprecise dosing, and failure to address the behavioral reinforcement of smoking and vaping. Ditch Labs is addressing these gaps with the DitchPen®, a proprietary, inhaled NRT device designed to deliver a controlled, stepwise reduction of nicotine to support sustained cessation. Engineered for optimal nicotine absorption, the DitchPen® mimics the PK profile of smoking, ensuring effective craving relief and withdrawal management. Paired with a digital therapeutic application, it provides structured dose reduction protocols and behavioral support, making quitting both scientifically precise and clinically effective. By combining pharmaceutical-grade replacement with a data-driven approach, Ditch Labs is pioneering the next generation of nicotine cessation therapies and aims to contribute to reducing the global burden of tobacco-related disease and mortality.